The randomized world is not without its imperfections: Reflections on the Women's Health Initiative Study

Fertility and Sterility

Volumn 78, Issue 5, 2002, Pages 951-956

  McDonough, Paul G ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; BREAST CANCER; CARDIOVASCULAR EFFECT; CLIMACTERIUM; CLINICAL TRIAL; DECISION MAKING; ESTROGEN THERAPY; FOLLOW UP; HEART DISEASE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; STROKE; SYMPTOMATOLOGY;

DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0036842423     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)04403-5     Document Type: Article

References (27)

1. Writing Group for the Women's Health Initiative . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
2. Freedman L., Anderson G., Kipnis V., Prentice R., Wang C.Y., Rossouw J., et al. Approaches to monitoring the results of long term disease prevention trials examples from the Women's Health Initiative . Control Clin Trials. 17:1996;509-525.
3. Tibshirani R. A plain man's guide to the proportional hazards model. Clin Invest Med. 5:1982;63-68.
4. The Women's Health Initiative Study Group . Design paper: design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 19:1998;61-109.
5. Brown B.W., Russell K. Methods correcting for multiple testing operating characteristics . Stat Med. 16:1997;2511-2528.
6. D'Agostino R.B. Controlling alpha in a clinical trial the case for secondary end points . Stat Med. 19:2000;763-766.
7. PEPI Trial Writing Group . Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 273:1995;199-208.
8. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology. 7:1987;1346-1358.
9. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.
10. Poole C. Low P-values or narrow confidence intervals which are more durable? Epidemiology. 12:2001;291-294.
11. Aickin M., Gensler H. Adjusting for multiple testing when reporting research results the Bonferroni vs Holm methods . Am J Public Health. 86:1996;726-728.
12. Pocock S.J., Clayton T.C., Altman D.G. Survival plots of time to event outcomes in clinical trials good practice and pitfalls . Lancet. 359:2002;1686-1689.
13. Figueiras A., Domenech-Massons J.M., Cadarso C. Regression models calculating the confidence interval of effects in the presence of interactions . Stat Med. 17:1998;2099-2105.
14. McGuigan K.A., Ganz P.A., Breant C. Agreement between breast cancer risk estimation methods. J Natl Cancer Inst. 88:1996;1315-1317.
15. Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 81:1989;1879-1886.
16. Claus E.B., Risch N., Thompson W.D. Autosomal dominant inheritance of early -onset breast cancer. Implications for risk prediction. Cancer. 73:1994;643-651.
17. Carlin B.P., Hodges J.S. Hierarchical proportional hazards regression models for highly stratified data. Biometrics. 55:1999;1162-1170.
18. Dupont W.D. Converting relative risks to absolute risks a graphical approach . Stat Med. 8:1989;641-651.
19. Rosner B., Spiegelman D., Willett W.C. Correction of logistic regression relative risk estimates and confidence intervals for measurement error the case of multiple covariates measured with error . Am J Epidemiol. 132:1990;734-745.
20. Armston A., Wood P. Hormone replacement therapy (estradiol-only preparations) can the laboratory recommend a concentration of plasma estradiol to protect against osteoporosis? Ann Clin Biochem. 39:2002;184-193.
21. Diver M.J. Monitoring of hormone replacement therapy. Lancet. 340:1992;1470-1471.
22. Klein K.O., Baron J., Colli M.J., McDonnell D.P., Cutler G.B. Jr. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest. 94:1994;2475-2480.
23. Henderson R.A. Chemistry with confidence should clinical chemistry require confidence intervals for analytical and other data . Clin Chem. 39:1993;929-935.
24. Lacey J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:2002;334-341.
25. Kasprzak L., Foulkes W.D., Shelling A.N. Hereditary ovarian carcinoma. BMJ. 318:1999;786-789.
26. DePasquale S.E., Giordano A., Donnenfeld A.E. The genetics of ovarian cancer molecular biology and clinical application . Obstet Gynecol Surv. 53:1998;248-256.
27. Enserink M. Epidemiology despite safety concerns, U.K. hormone study to proceed . Science. 297:2002;492.